What other benefits besides LDL lowering does inclisiran (Leqvio) have?
Inclisiran is designed to lower LDL cholesterol by reducing PCSK9 production in the liver. The main established “beyond LDL lowering” benefit signal is therefore still tied to cardiovascular outcomes: lowering LDL with inclisiran can reduce the risk of cardiovascular events in people who have cardiovascular disease or are at high risk.
Does Leqvio (inclisiran) reduce cardiovascular events, not just LDL?
Yes. Clinical evidence supports that inclisiran’s LDL lowering translates into fewer major cardiovascular events. In large outcomes data, the LDL reduction achieved with inclisiran was associated with a reduction in cardiovascular events compared with placebo in appropriate patient populations [1].
Are there benefits in people with statin intolerance or insufficient LDL response?
Inclisiran is used as an add-on option when LDL goals are not reached with statins (or when statins are not tolerated). For those patients, the practical benefit is achieving additional LDL lowering without requiring daily statin-style therapy changes, which can help people who cannot reach target LDL levels through standard regimens alone [2].
What “extra” might patients notice because dosing is less frequent?
Inclisiran is given as an injection on a maintenance schedule rather than daily oral medication. For many patients, the benefit beyond LDL lowering is adherence and convenience: fewer doses reduce the burden of long-term lipid management compared with therapies that require frequent dosing [2].
Is there evidence of effects on other lipid measures besides LDL?
Inclisiran’s primary lipid effect is lowering LDL cholesterol. Like other PCSK9-pathway therapies, it may also improve related atherogenic lipoprotein patterns (such as non-HDL cholesterol and apoB) as a downstream effect of lower LDL burden, but the strongest documented claims and labeling emphasis focus on LDL reduction and cardiovascular risk reduction [2].
How do clinicians think about “PCSK9 lowering” as a broader mechanism?
By lowering PCSK9, inclisiran increases hepatic LDL receptor activity, which increases clearance of LDL particles from the bloodstream. That mechanistic effect can be considered broader than a numeric LDL change because it targets the same pathway known to influence atherosclerotic risk through long-term LDL exposure [2].
What benefits might matter most for specific patient groups?
In practice, the “beyond LDL” value often shows up most for patients who:
have established cardiovascular disease or high risk,
need additional LDL lowering despite existing therapy,
or have difficulty achieving/maintaining targets with current oral options [2].
What benefits are not well proven yet?
Any claims that inclisiran improves outcomes in ways not mediated by LDL lowering (for example, effects on unrelated biomarkers or non-vascular endpoints) are not the main evidence-based case. The clearest benefit chain supported by available data is: LDL lowering through PCSK9 pathway inhibition leading to reduced cardiovascular events [1].
---
Sources
[1] https://www.nejm.org/doi/full/10.1056/NEJMoa1909701
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio